Tharimmune Inc (THAR)

Mar 31, 2025, 8:00 AM EDT - 4 days ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 24, 2025, 8:00 AM EDT - 11 days ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 4, 2025, 7:00 AM EST - 4 weeks ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Jan 27, 2025, 8:30 AM EST - 2 months ago

Tharimmune to Present at the Microcap Conference 2025

Dec 16, 2024, 8:00 AM EST - 3 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 6, 2024, 4:15 PM EST - 4 months ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Nov 18, 2024, 8:00 AM EST - 4 months ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 13, 2024, 8:00 AM EST - 5 months ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 4, 2024, 9:00 AM EST - 5 months ago

Tharimmune Announces Upcoming Conference Presentations

Oct 30, 2024, 8:00 AM EDT - 5 months ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 28, 2024, 9:00 AM EDT - 5 months ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Sep 30, 2024, 7:00 AM EDT - 6 months ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 16, 2024, 7:00 AM EDT - 7 months ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Jul 22, 2024, 8:30 AM EDT - 9 months ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 17, 2024, 8:30 AM EDT - 9 months ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jun 10, 2024, 8:00 AM EDT - 10 months ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Jan 29, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Dec 11, 2023, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Nov 30, 2023, 4:01 PM EST - 1 year ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 1 year ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 8:00 AM EST - 1 year ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 17, 2023, 7:00 AM EST - 1 year ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 6, 2023, 5:35 PM EST - 1 year ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Sep 22, 2023, 8:30 AM EDT - 1 year ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 11, 2023, 11:51 AM EDT - 1 year ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 8, 2023, 2:30 PM EDT - 1 year ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Aug 9, 2023, 8:47 AM EDT - 1 year ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Jul 20, 2023, 8:00 AM EDT - 1 year ago

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Jul 10, 2023, 8:47 AM EDT - 1 year ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Jul 6, 2023, 8:30 AM EDT - 1 year ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

May 15, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 2, 2023, 4:05 PM EDT - 2 years ago

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

Apr 27, 2023, 9:50 PM EDT - 2 years ago

Hillstream BioPharma Announces Pricing of Public Offering

Apr 27, 2023, 4:00 PM EDT - 2 years ago

Hillstream BioPharma Announces Proposed Public Offering

Apr 13, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Apr 12, 2023, 10:30 AM EDT - 2 years ago

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow

Apr 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data

Mar 28, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023

Feb 28, 2023, 9:45 AM EST - 2 years ago

Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023

Feb 15, 2023, 7:11 AM EST - 2 years ago

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Feb 13, 2023, 4:15 PM EST - 2 years ago

Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET

Feb 13, 2023, 7:11 AM EST - 2 years ago

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breas

Feb 10, 2023, 7:17 AM EST - 2 years ago

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer